Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Efficacy and safety of lisocabtagene maraleucel monotherapy in relapsed or refractory large B-cell lymphoma: A systematic review and meta-analysis of clinical trials and real-world studies

View Full Paper
Ask AI
Bookmark
Share

Authors

NKNidhi KejriwalAYAustin YangMAMojtaba Akhtari

Discussion

Loading...

Member takes

Overview

Meta-analysis reveals 78% overall response rate in relapsed large B-cell lymphoma patients using CAR T-cell therapy, suggesting potential for effective treatment decisions.

Key Points

  • Overall response rate reached 78%, indicating substantial efficacy of CAR T-cell therapy for large B-cell lymphoma.
  • The pooled analysis included 11 studies with 1206 patients, highlighting a robust dataset for efficacy evaluation.
  • Assessment followed meta-analysis protocols incorporating clinical trials and real-world data across diverse populations.
  • This analysis highlights the need for vigilance regarding common hematologic toxicities associated with CAR T-cell therapy.

Cite This Study

Kejriwal et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d8f6https://doi.org/10.1182/blood-2025-7232
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and Safety of Lisocabtagene Maraleucel in Relapsed or Refractory Large B-Cell Lymphoma: A Product-Specific Systematic Review and Meta-Analysis of Clinical Trials and Real-World Studies2026
  2. 2Outpatient (OP) use of lisocabtagene maraleucel (liso-cel) in patients (Pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): Real-world data from the CIBMTR registry2025
  3. 3Axi-cel vs. tisa-cel vs. liso-cel in R/R DLBCL: Meta-analysis of the efficacy-safety trade-off.2026
  4. 4Real-world evaluation of health care resource utilization, clinical effectiveness, and safety of lisocabtagene maraleucel and axicabtagene ciloleucel administered in the outpatient (OP) setting for R/R large B-cell lymphoma (LBCL)2025
  5. 5Patient-reported outcomes (PROs) with lisocabtagene maraleucel (liso-cel) in patients with third line or later (3L+) R/R MZL from the Phase 2 TRANSCEND FL study2025 · 1 citations